DCC has said that it has completed the acquisition of British generic drugs company Kent Pharmaceuticals in a move that it has said will significantly increase the scale of the company’s pharma business.
The deal is based on an enterprise valuation of €71.2 million, according to information previously released by DCC.
Kent is involved in the development, manufacture, sales, marketing and distribution of generic pharmaceuticals for the British, Irish and international markets. It...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team